JP2025509286A5 - - Google Patents

Info

Publication number
JP2025509286A5
JP2025509286A5 JP2024553397A JP2024553397A JP2025509286A5 JP 2025509286 A5 JP2025509286 A5 JP 2025509286A5 JP 2024553397 A JP2024553397 A JP 2024553397A JP 2024553397 A JP2024553397 A JP 2024553397A JP 2025509286 A5 JP2025509286 A5 JP 2025509286A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064054 external-priority patent/WO2023173026A1/en
Publication of JP2025509286A publication Critical patent/JP2025509286A/ja
Publication of JP2025509286A5 publication Critical patent/JP2025509286A5/ja
Pending legal-status Critical Current

Links

JP2024553397A 2022-03-10 2023-03-09 抗体-薬物コンジュゲートおよびその使用 Pending JP2025509286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318693P 2022-03-10 2022-03-10
US63/318,693 2022-03-10
PCT/US2023/064054 WO2023173026A1 (en) 2022-03-10 2023-03-09 Antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2025509286A JP2025509286A (ja) 2025-04-11
JP2025509286A5 true JP2025509286A5 (enExample) 2026-03-17

Family

ID=85873866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553397A Pending JP2025509286A (ja) 2022-03-10 2023-03-09 抗体-薬物コンジュゲートおよびその使用

Country Status (6)

Country Link
US (1) US20250205350A1 (enExample)
EP (1) EP4489790A1 (enExample)
JP (1) JP2025509286A (enExample)
CN (1) CN119173278A (enExample)
CA (1) CA3245693A1 (enExample)
WO (1) WO2023173026A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117024438B (zh) * 2022-07-29 2026-05-05 杭州爱科瑞思生物医药有限公司 依沙替康衍生物及其应用
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
CN119855820A (zh) * 2022-12-16 2025-04-18 上海齐鲁制药研究中心有限公司 喜树碱类化合物及其制备方法和用途
WO2024211236A2 (en) * 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN121985963A (zh) * 2023-04-05 2026-05-05 维硕公司 抗体偶联药物及其用途
WO2024211234A1 (en) * 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN117069793A (zh) * 2023-08-08 2023-11-17 杭州爱科瑞思生物医药有限公司 双功能接头化合物、抗体药物偶联物及其制备方法和应用
AU2024353116A1 (en) * 2023-09-28 2026-04-02 Hangzhou Adcoris Biopharma Co., Ltd Halogen-substituted exatecan amide derivative, preparation method therefor, and use thereof
AU2025217547A1 (en) * 2024-02-06 2026-08-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fused ring compound, and preparation method therefor and use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2443125B1 (en) 2009-06-17 2014-11-26 Threshold Pharmaceuticals, Inc. Camptothecin derivatives
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6871858B2 (ja) 2015-01-28 2021-05-19 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. 抗体薬物コンジュゲート
US11013816B2 (en) 2016-05-31 2021-05-25 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug
JP7359700B2 (ja) 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Cd38抗体薬物コンジュゲート
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
DK4516357T3 (da) * 2020-09-30 2026-04-27 Duality Biologics Suzhou Co Ltd Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
AU2022269073A1 (en) * 2021-05-07 2023-11-23 ALX Oncology Inc. Exatecan derivatives and antibody-drug conjugates thereof

Similar Documents

Publication Publication Date Title
TWI920652B (zh) 喜樹鹼結合物
JP6802340B2 (ja) 細胞障害性ベンゾジアゼピン誘導体
WO2022228495A1 (zh) 抗体偶联药物的制备方法及应用
CN107469089B (zh) 一种peg连接子及配基药物偶联物
JP2023529640A (ja) 治療用コンジュゲート
JP2026026483A (ja) 標的化デンドリマー複合体
JP2021513844A (ja) グリピカン3抗体およびそのコンジュゲート
JP2021121590A5 (enExample)
JP2017527562A (ja) 細胞毒性ベンゾジアゼピン誘導体
JP2010531140A5 (enExample)
CN120826405A (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2025539841A5 (enExample)
JP2011505371A5 (enExample)
CN119095625A (zh) 抗体-药物偶联物
JP2020534326A (ja) イムノコンジュゲートにおけるメチオニン酸化を防止する方法
JP2022514348A (ja) チオール多重リンカーを有するadc
AU2023387509A1 (en) An anti-tumor compound and use thereof
JP2016540826A5 (enExample)
CN108653746B (zh) 一种多载药点、高载药配基药物偶联物
JP2025515205A5 (enExample)
CN115038699A (zh) 苯并硒吩系化合物、包含其的药物组合物及抗体-药物缀合物
JP2024540402A5 (enExample)
CN115697967B (zh) 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
JP2025500404A5 (enExample)
JP2024540536A5 (enExample)